Tech Company Financing Transactions
Savara Pharmaceuticals Funding Round
On 3/1/2016, Savara Pharmaceuticals raised $20 million in Series C funding from private investors.
Transaction Overview
Company Name
Announced On
3/1/2016
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series C
Investors
Proceeds Purpose
The new financing will help support the AeroVanc Phase 3 trial, and expanding our pipeline with other new drugs for serious and life-shortening rare respiratory diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6836 Bee Cave Rd. Building 3, 200
Austin, TX 78746
USA
Austin, TX 78746
USA
Phone
Website
Email Address
Overview
Savara is a pharmaceutical company developing novel respiratory therapeutics utilizing our proprietary NanoCluster dry powder aerosol drug delivery platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Neville
Chief Financial Officer
David Lowrance
Chief Operating Officer
Taneli Jouhikainen
VP - Bus. Development
Peter Ginsberg
VP - Finance
Michael Ciesla
VP - General Counsel
Kate McCabe
VP - Regulatory Affairs
Cecilia Ganslandt
VP - Regulatory Affairs
Mette Vinge
Browse more venture capital transactions:
Prev: 2/29/2016: Centage venture capital transaction
Next: 3/1/2016: Borrowell venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs